Do Evidence-Based Interventions Work When Tested in the “Real World?” A Systematic Review and Meta-analysis of Parent Management Training for the Treatment of Child Disruptive Behavior

2013 ◽  
Vol 16 (1) ◽  
pp. 18-34 ◽  
Author(s):  
Daniel Michelson ◽  
Clare Davenport ◽  
Janine Dretzke ◽  
Jane Barlow ◽  
Crispin Day
Keyword(s):  
Systematic Review ◽  
Disruptive Behavior ◽  
Real World ◽  
Meta Analysis ◽  
Management Training ◽  
Parent Management Training ◽  
Evidence Based ◽  
The Real ◽  
Child Disruptive Behavior ◽  
Parent Management

Randomized Trial of Parent Management Training in Children With Tic Disorders and Disruptive Behavior

2006 ◽  
Vol 21 (8) ◽  
pp. 650-656 ◽  
Author(s):  
Lawrence Scahill ◽  
Denis G. Sukhodolsky ◽  
Karen Bearss ◽  
Diane Findley ◽  
Vanya Hamrin ◽  
...  
Keyword(s):  
Randomized Trial ◽  
Disruptive Behavior ◽  
Management Training ◽  
Tic Disorders ◽  
Parent Management Training ◽  
Parent Management

scholarly journals Predicting adult weight change in the real world: a systematic review and meta-analysis accounting for compensatory changes in energy intake or expenditure

2014 ◽  
Vol 39 (8) ◽  
pp. 1181-1187 ◽  
Author(s):  
E J Dhurandhar ◽  
K A Kaiser ◽  
J A Dawson ◽  
A S Alcorn ◽  
K D Keating ◽  
...  
Keyword(s):  
Systematic Review ◽  
Energy Intake ◽  
Real World ◽  
Weight Change ◽  
Meta Analysis ◽  
Adult Weight ◽  
The Real

scholarly journals Direct comparison of non-vitamin K antagonist oral anticoagulant versus warfarin for stroke prevention in non-valvular atrial fibrillation: a systematic review and meta-analysis of real-world evidences

2021 ◽  
Vol 73 (1) ◽  
Author(s):  
Yoga Waranugraha ◽  
Ardian Rizal ◽  
Mokhamad Fahmi Rizki Syaban ◽  
Icha Farihah Deniyati Faratisha ◽  
Nabila Erina Erwan ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Systematic Review ◽  
Vitamin K ◽  
Real World ◽  
Stroke Risk ◽  
Meta Analysis ◽  
Bleeding Risk ◽  
Vitamin K Antagonist ◽  
The Real ◽  
All Cause Mortality

Abstract Background To overcome the several drawbacks of warfarin, non-vitamin K antagonist oral anticoagulants (NOACs) were developed. Even though randomized controlled trials (RCTs) provided high-quality evidence, the real-world evidence is still needed. This systematic review and meta-analysis proposed to measure the safety and efficacy profile between warfarin and NOACs in non-valvular atrial fibrillation (NVAF) patients in preventing stroke. Results We collected articles about the real-world studies comparing warfarin and NOACs for NVAF patients recorded in electronic scientific databases such as Embase, ProQuest, PubMed, and Cochrane. The pooled hazard ratio (HR) and 95% confidence interval (CI) were estimated using the generic inverse variance method. A total of 34 real-world studies, including 2287288 NVAF patients, were involved in this study. NOACs effectively reduced the stroke risk than warfarin (HR 0.77; 95% CI 0.69 to 0.87; p < 0.01). Moreover, NOACs effectively lowered all-cause mortality risk (HR 0.71; 95% CI 0.63 to 0.81; p < 0.01). From the safety aspect, compared to warfarin, NOACs significantly reduced major bleeding risk (HR 0.68; 95% CI 0.54 to 0.86; p < 0.01) and intracranial bleeding risk (HR 0.54; 95% CI 0.42 to 0.70; p < 0.01). However, NOACs administration failed to decrease gastrointestinal bleeding risk (HR 0.78; 95% CI 0.58 to 1.06; p = 0.12). Conclusions In NVAF patients, NOACs were found to be more effective than warfarin at reducing stroke risk. NOACSs also lowered the risk of all-cause mortality, cerebral hemorrhage, and severe bleeding in NVAF patients compared to warfarin.

Real-World Effectiveness and Safety of Tofacitinib in Patients With Ulcerative Colitis: Systematic Review With Meta-Analysis

2021 ◽  
Author(s):  
Carlos Taxonera ◽  
David Olivares ◽  
Cristina Alba
Keyword(s):  
Systematic Review ◽  
Ulcerative Colitis ◽  
Clinical Trials ◽  
Real World ◽  
Meta Analysis ◽  
Mucosal Healing ◽  
Incidence Rates ◽  
Serious Adverse Events ◽  
The Real ◽  
Rate Of Response

Abstract Background Knowledge of the real-world effectiveness and safety of tofacitinib for ulcerative colitis (UC) is relevant to confirm the benefit observed in clinical trials. Methods This systematic review and meta-analysis evaluated the real-world effectiveness of tofacitinib for moderate to severely active UC. The primary outcome was clinical remission evaluated at week 8, weeks 12 to 16, and month 6. Secondary outcomes were response, corticosteroid-free remission, mucosal healing, colectomy, and safety. Results Seventeen studies with a total of 1162 patients with UC were included. Remission (11 studies) was achieved in 34.7% of patients at week 8 (95% confidence interval [CI], 24.4%-45.1%), 47% at weeks 12 to 16 (95% CI, 40.3%-53.6%), and 38.3% at month 6 (95% CI, 29.2%-47.5%) at month 6 duplicated. Response was achieved in 62.1%, 64.2%, 50.8%, and 41.8% of patients at week 8, weeks 12 to 16, month 6, and month 12, respectively. Corticosteroid-free remission (5 studies) was achieved in 38.4%, 44.3%, 33.6%, and 31% of patients at week 8, weeks 12 to 16, month 6, and month 12, respectively. Mucosal healing was achieved in 48.3% and 45.3% of patients at week 8 and weeks 12 to 16, respectively. Patients who were biologic-naïve (11.6%) had a significantly higher rate of response at week 8 (1.38; 95% CI, 1.03-1.84). The incidence rates of serious adverse events and herpes zoster was 8.9 and 6.9 per 100 patient-years, respectively. Conclusions This meta-analysis of real-world studies confirms the effectiveness of tofacitinib in a highly refractory population of patients with moderate to severely active UC. Tofacitinib showed an acceptable safety profile. These findings were consistent with clinical trials and further support the use of tofacitinib in UC.

Sign in / Sign up

Export Citation Format

Share Document